Welcome to our dedicated page for Vivopower International news (Ticker: VIVO), a resource for investors and traders seeking the latest updates and insights on Vivopower International stock.
VivoPower PLC reports company developments tied to its AI data center infrastructure, Power-to-X platform and powered land assets. Recurring announcements cover data center asset activity, reserve-market demand response at the Mo i Rana, Norway site, conference presentations and updates on the company's sovereign AI compute infrastructure strategy.
Company news also covers capital-structure actions, including share conversion matters and registration-statement changes, as well as governance and advisory council updates, material agreements, shareholder voting matters, operating results and financial results.
Meridian Bioscience (NASDAQ: VIVO) reported Q4 and FY2021 financial results with consolidated net revenues of $76.2 million, up 19% year-over-year. For FY2021, revenues rose 25% to $317.9 million, driven by a 43% increase in the Life Science segment and $111.9 million from COVID-19 products. Operating income for Q4 was $8.5 million (11% margin), and FY2021 was $93 million (29% margin). The company faces challenges from product recalls and upcoming FDA approvals. Guidance for FY2022 estimates revenues between $285-$300 million with an adjusted operating margin of 21%-22%.
Meridian Bioscience, Inc. (NASDAQ: VIVO) announced that the Revogene® SARS-CoV-2 assay has received Emergency Use Authorization (EUA) from the FDA. Shipments are expected to begin before December 31, 2021. This molecular diagnostic test provides results in as little as 47 minutes, boasting a positive predictive agreement (PPA) and negative predictive agreement (NPA) of 97.7%. The assay aims to enhance COVID-19 testing capacity for healthcare systems, addressing the ongoing demand for accurate detection amid emerging variants.
Meridian Bioscience (NASDAQ: VIVO) announced the launch of two innovative Air-Dryable™ qPCR Mixes, enhancing direct detection of DNA or RNA from urine samples. These mixes address the inhibition challenges associated with crude urine samples, allowing for faster and more sensitive molecular assays without the need for tedious purification. This innovative technology simplifies assay setup, making it cost-effective and suitable for point-of-care applications. Meridian's commitment to innovation positions it to deliver superior diagnostic solutions, improving patient compliance and satisfaction.
Meridian Bioscience (NASDAQ: VIVO) will announce its fourth quarter and full year 2021 financial results on November 12, 2021. The event will feature a conference call at 10:00 a.m. Eastern Time led by CEO Jack Kenny and CFO Bryan Baldasare. A live webcast will be available for investors, alongside a telephone option for participants. Additionally, a recorded version will be accessible for one year post-event. Meridian specializes in diagnostic products across various sectors, providing essential solutions globally.
Meridian Bioscience (NASDAQ: VIVO) launched its new Air-Dryable™ Direct RNA/DNA qPCR Blood Mix, designed for rapid and sensitive detection of viral and bacterial infections directly from blood samples. This innovative product simplifies the development of molecular diagnostics by eliminating the need for costly DNA/RNA purification. Compatible with air-drying, it replaces traditional lyophilization methods, reducing manufacturing costs and enhancing workflow efficiency. The technology supports applications in cancer management and forensic analyses, emphasizing Meridian's commitment to accelerating diagnostic solutions.
Meridian Bioscience recently launched two innovative Air-Dryable™ Master Mixes: the Air-Dryable™ Direct DNA qPCR Stool and Air-Dryable™ Direct RNA/DNA qPCR Stool Mixes. These products facilitate room-temperature stable molecular diagnostics from crude stool samples, eliminating the need for complex purification steps. This technology enhances assay speed and sensitivity, making it valuable for applications like gastrointestinal disease diagnosis. Meridian aims to simplify the development of diagnostic assays and is committed to accelerating solutions in the diagnostic industry. Shares are traded on NASDAQ under the symbol VIVO.
Meridian Bioscience announced the launch of its new Air-Dryable™ Direct DNA qPCR Saliva and Air-Dryable™ Direct RNA/DNA qPCR Saliva Mixes, enabling room-temperature stable molecular assays from saliva and sputum samples. These products address challenges in diagnostics due to PCR inhibitors in saliva, allowing for direct diagnosis without extensive sample processing. Dr. Lourdes Weltzien highlighted benefits such as reduced healthcare worker exposure and cost savings for manufacturers. Meridian aims to simplify diagnostic development and improve assay performance.
Meridian Bioscience (NASDAQ: VIVO) announced an expansion of the voluntary recall of its LeadCare Test Kits for lead detection in blood due to control test failures. The recall, initiated in May 2021, affects various lot numbers and underscores the risk of underestimating blood lead levels. The company recommends discontinuing the use of these kits and evaluating patient test results with alternative methods. The U.S. FDA has been notified of the situation, and product distribution has been paused until further notice.
Meridian Bioscience, Inc. (NASDAQ: VIVO) announced its participation in the H. C. Wainwright 23rd Annual Global Investment Conference. CEO Jack Kenny's pre-recorded presentation will be accessible starting September 13, 2021, at 7:00 am ET.
The presentation can be viewed for 90 days on the Company’s Investor Relations website. Meridian, a life science company, develops and distributes innovative diagnostic products, serving clients in over 70 countries. For details on the conference, visit the official website.
Meridian Bioscience reported Q3 2021 net revenues of $63.5 million, a 25% decline from Q3 2020 but a 31% increase from Q3 2019. The diagnostics segment grew 44% year-over-year to $31.2 million, while the life science segment decreased by 49% to $32.3 million. Operating income fell 55% to $15.7 million, though adjusted operating income was $12.9 million with a margin of 20%. The company reaffirmed its 2021 revenue guidance of $308 million to $314 million.